Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
February 28 2023 - 3:05PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
announced that Mike Sherman, Chief Executive Officer, will
participate in a Targeted Oncology Panel at the Cowen and Company
43rd Annual Health Care Conference on Tuesday, March 7, 2023 at
2:10 p.m. ET.
An audio webcast of the panel discussion will be available on
the Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
CONTACTS:
Michelle LaSpaluto919 972-7115ir@chimerix.com
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Nick Lamplough / Dan Moore / Tanner
KaufmanJoele Frank, Wilkinson Brimmer Katcher(212)
355-4449
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024